Felvizumab
Highest phase reached
Phase 2
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Antibody
- Drug name
- Felvizumab
- felvizumab
- Felvizumab
- felvizumab [INN]
- FELVIZUMAB [USAN]
- Felvizumab [WHO-DD]
- felvizumab inn
- felvizumab usan
- felvizumab who dd
- IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL, G-CHAIN ANTI-RESPIRATORY SYNCYTIAL VIRUS), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL K-CHAIN, DIMER
- IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL, G-CHAIN ANTI-RESPIRATORY SYNCYTIAL VIRUS), DISULPHIDE WITH HUMAN-MOUSE MONOCLONAL K-CHAIN, DIMER
- immunoglobulin g 1 human mouse monoclonal g chain anti respiratory syncytial virus disulfide with human mouse monoclonal k chain dimer
- immunoglobulin g 1 human mouse monoclonal g chain anti respiratory syncytial virus disulphide with human mouse monoclonal k chain dimer
- immunoglobulin g1 anti respiratory syncytial virus human mouse monoclonal gamma 1 chain disulfide with human mouse monoclonal kappa chain dimer
- IMMUNOGLOBULIN G1, ANTI-(RESPIRATORY SYNCYTIAL VIRUS) (HUMAN-MOUSE MONOCLONAL .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL .KAPPA.-CHAIN, DIMER
- rshz 19
- RSHZ-19
- rshz19
- RSHZ19
- sb 209763
- SB 209763
- SB-209763
- sb209763
- SB209763
- CAS registry numbers
- 167747-20-8
- ChEMBL ID
- CHEMBL2109101
- FDA ingredient codes (UNII)
- W9ZA2K5Q83
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -mab; -mab
Mechanisms of action
- Mechanism
- Fusion glycoprotein F0 inhibitor
- Action type
- Inhibitor
- Target
- Fusion glycoprotein F0
- Protein identifier
- P03420
Open Targets mechanisms
- Mechanism
- Fusion glycoprotein F0 inhibitor
- Action type
- Inhibitor
- Target
- Fusion glycoprotein F0
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (4)
- A Phase 2 Study to Describe the Safety and Immunogenicity of Respiratory Syncytial Virus Vaccine IN006 in Healthy Participants Aged 60 Years and Older
- A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults
- RSV Vaccine Response in Stem Cell and CAR-T Therapy Recipients
- TARSILA Real-World Evidence Study